D
Dianjing Biomedical Technology (Suzhou)
Developing innovative ocular and recombinant human collagen-based therapeutics
About Dianjing Biomedical Technology (Suzhou)
Eluminex Biosciences is a clinical-stage biotechnology firm that specializes in the research and development of innovative therapeutics. The company's primary focus is on ophthalmology and recombinant human collagen technology. In simpler terms, they are working on advanced treatments for eye conditions and therapies based on human collagen, a protein that provides structure to various body parts.
The company operates in the global healthcare market, with a significant emphasis on China. Their business model revolves around the development and commercialization of their therapeutics. They generate revenue through the successful launch and sales of these treatments, as well as through strategic partnerships and financing rounds.
Eluminex has recently secured over $40 million in Series B financing, following an initial $50 million Series A financing in 2020. This funding will allow the company to further develop its innovative pipeline of treatments and initiate additional clinical-stage projects. The company has also completed a B+ round of financing, raising more than $50 million in venture capital in 2023 alone. This funding will be used to advance multiple preclinical and clinical programs rapidly.
In summary, Eluminex Biosciences is a promising biotech startup, making significant strides in the development of innovative ocular and collagen-based therapeutics. Their recent successful financing rounds demonstrate strong investor confidence and provide the necessary capital to continue their research and development efforts.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2023 | $10M | $250M | Oriza FOFs · Suzhou International Development Venture Capital Holding | ↗ |
| SERIES BOther financing | Feb 2023 | $40M | $250M | Oriza Holdings · Cenova Capital · Lilly Asia Ventures · Quan Capital | ↗ |
Growth signals
Latest recorded traffic for Dianjing Biomedical Technology (Suzhou) is 610 monthly website visits, up 1933.3% over the last three months. Dianjing Biomedical Technology (Suzhou)'s team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Dianjing Biomedical Technology (Suzhou) in the Huangpu ecosystem
The Dianjing Biomedical Technology (Suzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Lilly Asia Ventures
Quan Capital
GL Ventures
Cenova Capital
Oriza Holdings- GFGuangzhou YUEXIU Industrial Investment Fund
3E Bioventures
Oriza FOFs
Suzhou International Development Venture Capital Holding
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dianjing Biomedical Technology (Suzhou) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dianjing Biomedical Technology (Suzhou)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










